Lumida
/PRTA
⌘K
Prothena Corporation PLC

Prothena Corporation PLC

PRTA
$8.93USD-1.00%-0.09 today

MARKET CAP

458.4M

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $9

52W RANGE

$8
$12

AI Summary

Stalk
TrimMedium

PRTA remains in a Stage 4 decline with a clear lower-high/lower-low sequence and price trading below its major moving averages. The recent short-covering rally has pushed price into declining 9/21/50 EMAs and verging on resistance at the 200DMA, creating an opportune zone to trim bearish positions. With medium- and long-term trends firmly down and overbought short-term indicators, fading this rally into moving-average resistance aligns with the prevailing downtrend.

  • Advancing two partnered programs into Phase III clinical trials
  • End-2024 cash $472M vs. projected $168–175M burn in 2025
  • Projected 2025 net loss of $244M underscores heavy cash consumption
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$200.6M$53.9M$91.4M$135.2M$9.7M
YoY %+23414.3%-73.1%+69.5%+47.9%-92.8%
P / Sales11.9x47.0x22.4x5.5x53.1x
EV / Sales9.8x36.4x17.2x2.5x26.1x
Gross Profit, Adj.$200.6M$53.9M$91.4M$135.2M$9.7M
YoY %+23414.3%-73.1%+69.5%+47.9%-92.8%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit9.8x36.4x17.2x2.5x26.1x
EBITDA, Adj.$78.8M$-130.8M$-190.1M$-153.7M$-183.7M
YoY %+170.8%-266.1%-45.3%+19.2%-19.5%
Margin %39.3%-242.7%-208.1%-113.7%-1896.6%
EV / EBITDA24.9x-15.0x-8.2x-2.2x-1.4x
EBIT$72.0M$-131.6M$-191.0M$-154.6M$-214.6M
YoY %+163.8%-282.8%-45.2%+19.1%-38.9%
Margin %35.9%-244.1%-209.1%-114.4%-2216.4%
EV / EBIT27.2x-14.9x-8.2x-2.2x-1.2x
Net Income$67.0M$-116.9M$-147.0M$-122.3M$-244.1M
YoY %+160.3%-274.6%-25.7%+16.8%-99.6%
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (GAAP)$1.38-$2.47-$2.76-$2.27-$4.53
YoY %+149.6%-279.0%-11.7%+17.8%-99.6%